Third and fourth fluoroquinolones generations;Les fluoroquinolones de troisième et quatrième générations

Journal de Pharmacie de Belgique

Volumn 56, Issue 6, 2001, Pages 137-148

  Rossi, C ^a   Sternon, J ^a  

^a Site de Baudour ^*  (Côte d’Ivoire)

Author keywords

Adverses events and interactions; Classification; Indications; Mechanism of action and of resistance; New fluoroquinolones

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; CIPROFLOXACIN; CLARITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; FLEROXACIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE;

AREA UNDER THE CURVE; BACTERIAL INFECTION; BACTERIAL MUTATION; BACTERICIDAL ACTIVITY; BACTEROIDES FRAGILIS; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CLASSIFICATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS INFLUENZAE; HUMAN; IN VITRO STUDY; ISOMERISM; KLEBSIELLA PNEUMONIAE; LEGIONELLA PNEUMOPHILA; MINIMUM INHIBITORY CONCENTRATION; MYCOPLASMA PNEUMONIA; NEUROLOGIC DISEASE; NONHUMAN; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; STRUCTURE ACTIVITY RELATION;

ANTI-INFECTIVE AGENTS; BACTERIA; DRUG RESISTANCE, MICROBIAL; FLUOROQUINOLONES; HUMANS;

EID: 0035731374     PISSN: 00472166     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Fluoroquinolones
2. New uses for new and old quinolones and the challenge of resistance
3. Structure-activity and structure-side effect relationship of the quinolones antibacteriais
4. Mechanisms of action and resistance of older newer FQ
5. DNA gyrase topoisomerase IV, and the 4-quinolones
6. Topoisomerase IV is a target of quinolones in Escherichia coli
7. Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases
8. Primary targets of fluoroquinolones in Streptococcus pneumoniae
9. Mechanisms and frequency of resistance to gatifloxacin in comparison with ciprofloxacin in Staphylococcus aureus
10. Efflux pump-mediated quinolone resistance in Staphylococcus aureus strains wild type for gyrA, gyrB, grlA, and norA
11. Mechanisms responsible for cross-resistance and dichotomous resistance among the quinolones
12. In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes and Staphylococcus aureus
13. Decreased susceptibility of Streptococcus pneumoniae to FQ in Canada
14. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: A case-control study
15. The fluoroquinolones
16. Comparative in vitro of gemifloxacin, other quinolones, and nonquinolone antimicrobials against obligately anaerobic bacteria
17. A risk-benefit assesment of levofloxacin
18. Clinical pharmacology of the FQ: Studies in human dynamic-kinetic models
19. What have we learned from pharmacokinetic and pharmacodynamic theories?
20. In vitro activities of sitafloxacin and six other FQ against 8.796 clinical bacterial isolates
21. Antimicrobial activity of advanced-spectrum FQ tested against more than 2.000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States
22. Moxifloxacin: Review of the microbiological, pharmacological safety features
23. Moxifloxacin: A review of its safety profile based on worldwide clinical trials
24. Fluoroquinolone toxicity profiles: A review focusing on newer agents
25. QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin
26. Magnesium deficiency induces joint cartilage lesions in juvenile rats which are identical to quinolones-induced arthropathy
27. Newer fluoroquinolones and the management of respiratory tract infections
28. Clinical experience in Germany of treating community-acquired respiratory infections with the new 8-methoxyfluoroquinolone, moxifloxacin
29. Acute community-acquired pneumonia: Current diagnosis and treatment
30. New antibiotics for community-acquired lower respiratory tract infections: Improved activity at a cost?
31. Management of community-acquired pneumonia in the era of pneumococcal resistance
32. Practice guidelines for the management of community-acquired pneumonia in adults
33. Principles of appropriate antibiotic use for treatment of acute respiratory tract infections in adults: Background, specific aims, and methods
34. Canadian guidelines for the initial management of community-acquired pneumonia: An evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society
35. Guidelines for the management of adults with community-acquired pneumonia
36. Importance of a typical pathogens of community-acquired pneumonia
37. In vitro study on the antimicrobial activity of various antibiotics against clinical isolates of Streptococcus pneumoniae from Belgium collected during winter 1998-1999
38. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia
39. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus afniaxone and/or afuroxime axetil in treatment of adults with community-acquired pneumonia
40. Comparative study of levofloxacin and amoxycillin clavulanic acid in adults with mild-to-moderate community-acquired pneumonia
41. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia
42. Oral moxifloxacin versus high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults